Intracerebral Hemorrhage
Conditions
Brief summary
A multicenter, open-label phase 2a trial of CN-105 in patients with supratentorial intracerebral hemorrhage (ICH). Patients will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants (approximately 60) will receive CN-105 administered intravenously (IV) for a 30-minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days). Participants will be monitored daily throughout the Treatment phase of the study (up to a maximum of 5 days) and will receive standard-of-care treatment for the duration of the study. Additional protocol assessments will be required during the Treatment phase. After discharge from the hospital, participants will enter a 3-month Follow-up phase, with a clinic visit at 30 days and a follow-up telephone interview with telephone-validated Modified Rankin Scale (mRS) at 90 days after first dose of study agent. Funding Source - FDA OOPD
Interventions
DRUGCN-105
Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)
Sponsors
Duke Clinical Research Institute
PharPoint Research, Inc.
AegisCN LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Has given written informed consent to participate in the study in accordance with required regulations; if a participant is not capable of providing informed consent, written consent must be obtained from the participant's legally authorized representative (LAR). 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Is male or female, age 30 to 80 years, inclusive. 4. Has a confirmed diagnosis of spontaneous supratentorial ICH. 5. Able to receive first dose of study drug ≤ 12 hours after onset of ICH symptoms, such as alteration in level of consciousness, severe headache, nausea, vomiting, seizure, and/or focal neurological deficits, or last-known well time. 6. Has an interpretable and measurable diagnostic CT scan. 7. Has a Glasgow Coma Scale (GCS) score ≥ 5 on presentation 8. Has a National Institutes of Health Stroke Scale (NIHSS) score ≥ 4. 9. Has systolic BP (SBP) \< 200 mm Hg at enrollment.
Exclusion criteria
1. Is pregnant or lactating. 2. Has a temperature greater than 38.5°C at Screening. 3. Has ICH resulting from trauma. 4. Has infratentorial hemorrhage (any involvement of the midbrain or lower brainstem as demonstrated by radiograph or complete third nerve palsy). 5. Has primary intraventricular hemorrhage deemed to be at high risk for obstructive hydrocephalus, or extra-axial (ie, subarachnoid or subdural) extension of hemorrhage. 6. Has radiographic evidence of underlying tumor. 7. Has an unstable mass or evolving intracerebral compartment syndrome. 8. Has a ruptured aneurysm, arteriovenous malformation, or vascular anomaly. 9. Has a platelet count \< 100,000/mL. 10. Has an international normalized ratio (INR) \< 1.6 or irreversible coagulopathy either due to medical condition or detected before screening. 11. In the opinion of the investigator is unstable and would benefit from supportive care rather than supportive care plus CN-105. 12. In the opinion of the investigator has any contraindication to the planned study assessments, including CT and MRI. 13. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which, in the opinion of the investigator, unacceptably increases the individual's risk by participating in the study. 14. Concomitant enrollment in another interventional study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 30 days | Record In-hospital 30-day mortality |
| In-hospital neurological deterioration | 30 days | Increase of National Institutes of Health Stroke Scale (NIHSS), \> 2 from baseline, persisting more than 24 hours, and unrelated to sedation. |
| CN-105 safety assessment | 90 days | Number and severity of AEs throughout the duration of the study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement in 30-day functional outcomes | 30 days | Compare participants treated with CN-105 with matched controls |
| Improvement in 30-day mortality | 30 days | Compare participants treated with CN-105 with matched controls |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory CT to evaluate progression of edema | 30 days | To investigate feasibility of noncontrast head computed tomography (CT) as a radiographic surrogate to evaluate progression of perihematomal edema |
| Exploratory neuroinflammatory biomarker assessment to evaluate progression of edema | 90 days | To investigate feasibility of using serial biochemical markers of neuroinflammation and neuronal injury as a surrogate measure of perihematomal edema and clinical outcome in the setting of spontaneous ICH |
| Exploratory MRI to evaluate progression of edema | 30 days | To investigate feasibility magnetic resonance imaging (MRI) radiographic surrogate measures to evaluate progression of perihematomal edema |
Countries
United States
Outcome results
None listed